A Study in Japanese Participants With Moderate-to-Severe Psoriasis

A Multicenter, Open-Label, Long-Term Study to Evaluate the Efficacy and Safety of LY2439821 in Japanese Patients With Moderate-to-Severe Psoriasis

This study will assess the safety and efficacy of ixekizumab in participants with moderate to severe psoriasis in Japan.

Inclusion Criteria:

• Men must agree to use a reliable method of birth control during the study
• Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
• Candidates for phototherapy and/or systemic therapy
• Present with chronic psoriasis based on a confirmed psoriasis diagnosis for at least 6 months prior to enrollment
• At least 10% Body Surface Area (BSA) of Psoriasis at screening and at enrollment for participants with plaque psoriasis
• Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at enrollment for participants with plaque psoriasis

Exclusion Criteria:

• History of drug-induced psoriasis
• Concurrent or recent use of any biologic agent
• Received systemic psoriasis therapy [such as psoralen and ultraviolet A (PUVA) light therapy] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment for participants with plaque psoriasis
• Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study
• Have participated in any study with interleukin-17(IL-17) antagonists, including ixekizumab
• Serious disorder or illness other than psoriasis
• Serious infection within the last 3 months
• Breastfeeding or nursing (lactating) women
• Clinically significant flare of psoriasis during the 12 weeks prior to enrollment for participants with plaque psoriasis